# Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children

> **NCT03680417** · PHASE4 · COMPLETED · sponsor: **PT Bio Farma** · enrollment: 590 (actual)

## Conditions studied

- Safety Issues
- Immunogenicity

## Interventions

- **BIOLOGICAL:** Measles-Rubella (MR) Vaccine

## Key facts

- **NCT ID:** NCT03680417
- **Lead sponsor:** PT Bio Farma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-16
- **Primary completion:** 2018-02-26
- **Final completion:** 2018-08-01
- **Target enrollment:** 590 (ACTUAL)
- **Last updated:** 2019-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03680417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03680417, "Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03680417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*